Genomma Lab Internacional Overview
- Year Founded
-
1996
- Status
-
Public
- Employees
-
1,665
- Stock Symbol
-
LABB
- Investments
-
6
- Share Price
-
$0.82
- (As of Friday Closing)
Genomma Lab Internacional General Information
Description
Genomma Lab Internacional SAB de CV is a specialty and generic drug manufacturer. The company's stated goal is to improve and preserve the health and well-being of people through innovative, safe, and effective products. Genomma operates a wide variety of brands to serve different consumer needs, including pregnancy, pain medication, and deodorant. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
Contact Information
Website
www.genommalab.comCorporate Office
- Avenida Antonio Dovalí Jaime, number 70, tower C, floor 2, office A
- Colonia Santa Fe. CP
- Mexico City, 01210
- Mexico
Corporate Office
- Avenida Antonio Dovalí Jaime, number 70, tower C, floor 2, office A
- Colonia Santa Fe. CP
- Mexico City, 01210
- Mexico
Genomma Lab Internacional Stock Performance
As of 13-Nov-2026, Genomma Lab Internacional’s stock price is $0.82. Its current market cap is $803M with 978M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.82 | $0.84 | $0.68 - $1.13 | $803M | 978M | 3.89M | $0.10 |
Genomma Lab Internacional Financials Summary
As of 30-Sep-2026, Genomma Lab Internacional has a trailing 12-month revenue of $969M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 973,409 | 1,243,164 | 1,389,110 | 1,073,789 |
| Revenue | 968,969 | 912,472 | 1,015,638 | 927,396 |
| EBITDA | 190,498 | 181,836 | 220,102 | 147,602 |
| Net Income | 96,528 | 83,958 | 81,500 | 57,800 |
| Total Assets | 1,402,774 | 1,315,496 | 1,114,011 | 1,218,802 |
| Total Debt | 443,436 | 423,536 | 313,987 | 367,419 |
Genomma Lab Internacional Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Genomma Lab Internacional Comparisons
Industry
Financing
Details
Genomma Lab Internacional Competitors (20)
One of Genomma Lab Internacional’s 20 competitors is Glenmark Pharmaceuticals, a Corporation company based in Mumbai, India.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Glenmark Pharmaceuticals | Corporation | Mumbai, India | ||||
| SynCore Biotechnology Company | Corporation | Yilan City, Taiwan | ||||
| Shionogi | Corporation | Osaka, Japan | ||||
| Cipla | Corporation | Mumbai, India | ||||
| Novavax | Corporation | Gaithersburg, MD |
Genomma Lab Internacional Patents
Genomma Lab Internacional Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2013028049-A2 | Composition for the percutaneous administration of active compounds providing a suitable treatment for androgenetic alopecia | Inactive | 25-Aug-2011 | ||
| WO-2013028049-A3 | Composition for the percutaneous administration of active compounds providing a suitable treatment for androgenetic alopecia | Inactive | 25-Aug-2011 |
Genomma Lab Internacional Signals
Genomma Lab Internacional Investments & Acquisitions (6)
Genomma Lab Internacional’s most recent deal was a Corporate Asset Purchase with Isa Laboratorios (Treg Brand). The deal was made on 25-Jul-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Isa Laboratorios (Treg Brand) | 25-Jul-2024 | Corporate Asset Purchase | Buildings and Property | ||
| Suero Oral | 24-Jul-2024 | Merger/Acquisition | Beverages | ||
| Joint Venture (Genomma Lab Internacional/Oravax Medical) | 18-Nov-2021 | Joint Venture | Drug Discovery | ||
| Dr. Reddy's Laboratories (Bufferin Brand) | 14-Jun-2018 | Corporate Asset Purchase | Buildings and Property | ||
| Sheffield Pharmaceuticals (Cheracol D and Rose Milk) | 14-Jun-2018 | Corporate Asset Purchase | Buildings and Property |
Genomma Lab Internacional ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
28.06 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Pharmaceuticals
Subindustry
of 354
Rank
Percentile
Genomma Lab Internacional Exits (1)
Genomma Lab Internacional’s most recent exit was on 30-Jun-2014 from Marzam. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Marzam | 30-Jun-2014 | Completed |
|
Genomma Lab Internacional Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Suero Oral | Miami, FL | 1999 |
Genomma Lab Internacional FAQs
-
When was Genomma Lab Internacional founded?
Genomma Lab Internacional was founded in 1996.
-
Where is Genomma Lab Internacional headquartered?
Genomma Lab Internacional is headquartered in Mexico City, Mexico.
-
What is the size of Genomma Lab Internacional?
Genomma Lab Internacional has 1,665 total employees.
-
What industry is Genomma Lab Internacional in?
Genomma Lab Internacional’s primary industry is Personal Products.
-
Is Genomma Lab Internacional a private or public company?
Genomma Lab Internacional is a Public company.
-
What is Genomma Lab Internacional’s stock symbol?
The ticker symbol for Genomma Lab Internacional is LABB.
-
What is the current stock price of Genomma Lab Internacional?
As of 13-Nov-2026 the stock price of Genomma Lab Internacional is $0.82.
-
What is the current market cap of Genomma Lab Internacional?
The current market capitalization of Genomma Lab Internacional is $803M.
-
What is Genomma Lab Internacional’s current revenue?
The trailing twelve month revenue for Genomma Lab Internacional is $969M.
-
Who are Genomma Lab Internacional’s competitors?
Glenmark Pharmaceuticals, SynCore Biotechnology Company, Shionogi, Cipla, and Novavax are some of the 20 competitors of Genomma Lab Internacional.
-
What is Genomma Lab Internacional’s annual earnings per share (EPS)?
Genomma Lab Internacional’s EPS for 12 months was $0.10.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process